<DOC>
	<DOC>NCT02301936</DOC>
	<brief_summary>This study will evaluate the safety, tolerability, and antiviral efficacy of ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) administered for 12 or 24 weeks in adults with genotype 1 or 4 hepatitis C virus (HCV) infection with sickle cell disease (SCD).</brief_summary>
	<brief_title>Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 or 24 Weeks in Genotype 1 or 4 HCV Infected Adults With Sickle Cell Disease</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Anemia, Sickle Cell</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<mesh_term>Ledipasvir</mesh_term>
	<mesh_term>Ledipasvir, sofosbuvir drug combination</mesh_term>
	<criteria>Chronic genotype 1 or 4 infected patients with sickle cell disease HCV RNA â‰¥ 1,000 IU/mL at screening Cirrhosis determination by transient elastography Screening laboratory values within defined thresholds Use of two effective contraception methods if female of childbearing potential or sexually active male Pregnant or nursing female Coinfection with HIV or hepatitis B virus (HBV) Current or prior history of clinical hepatic decompensation Hepatocellular carcinoma (HCC) or other malignancy (with exception of certain resolved skin cancers) History of clinically significant illness or any other medical disorder that may interfere with treatment, assessment or compliance with the protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Sickle Cell Disease</keyword>
	<keyword>Gilead</keyword>
	<keyword>Hepatitis C</keyword>
</DOC>